On Monday, AnaptysBio Inc (NASDAQ: ANAB) opened higher 9.54% from the last session, before settling in for the closing price of $17.08. Price fluctuations for ANAB have ranged from $12.21 to $41.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 247.37%. Company’s average yearly earnings per share was noted -5.67% at the time writing. With a float of $28.30 million, this company’s outstanding shares have now reached $30.47 million.
Considering the fact that the conglomerate employs 136 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 98.03%, operating margin of -125.93%, and the pretax margin is -159.1%.
AnaptysBio Inc (ANAB) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of AnaptysBio Inc is 7.73%, while institutional ownership is 124.12%. The most recent insider transaction that took place on Dec 30 ’24, was worth 842,060. In this transaction Director of this company bought 65,184 shares at a rate of $12.92, taking the stock ownership to the 7,860,180 shares. Before that another transaction happened on Dec 31 ’24, when Company’s Director bought 13,268 for $12.93, making the entire transaction worth $171,513. This insider now owns 7,873,448 shares in total.
AnaptysBio Inc (ANAB) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -5.67% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.00% during the next five years compared to -7.30% drop over the previous five years of trading.
AnaptysBio Inc (NASDAQ: ANAB) Trading Performance Indicators
Check out the current performance indicators for AnaptysBio Inc (ANAB). In the past quarter, the stock posted a quick ratio of 9.51. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.29.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -5.20, a number that is poised to hit -1.30 in the next quarter and is forecasted to reach -5.33 in one year’s time.
Technical Analysis of AnaptysBio Inc (ANAB)
Compared to the last year’s volume of 1.03 million, its volume of 1.13 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 62.96%. Additionally, its Average True Range was 1.62.
During the past 100 days, AnaptysBio Inc’s (ANAB) raw stochastic average was set at 32.16%, which indicates a significant decrease from 64.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 68.17% in the past 14 days, which was lower than the 122.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.71, while its 200-day Moving Average is $25.26. Nevertheless, the first resistance level for the watch stands at $20.45 in the near term. At $22.20, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.67. If the price goes on to break the first support level at $17.23, it is likely to go to the next support level at $15.76. Now, if the price goes above the second support level, the third support stands at $14.01.
AnaptysBio Inc (NASDAQ: ANAB) Key Stats
There are currently 30,667K shares outstanding in the company with a market cap of 573.78 million. Presently, the company’s annual sales total 91,280 K according to its annual income of -145,230 K. Last quarter, the company’s sales amounted to 43,110 K and its income totaled -21,780 K.
